Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The LEADER cardiovascular outcomes trial (N=9,340) demonstrated cardiovascular safety and a reduction in major adverse cardiovascular events with liraglutide 1.8 mg in patients with type 2 diabetes [9]
Treatment is available in all 50 states
Explore Eight Sleeps ongoing sleep research to learn more about the factors that shape sleep quality.
Acute pancreatitis has been reported with tirzepatide use
None requires an in-person visit
Trial enrollment uses a study protocol, informed consent, screening, and scheduled monitoring
US$ 26.78
US$ 21.29
US$ 22.36
US$ 25.32
US$ 23.30
US$ 28.60
